Skip to main content

Full text of "USPTO Patents Application 09804625"

See other formats


45 

What is claimed Is: 

1. An osteogenic protein comprising an amino acid sequence 
selected from the group consisting of: 

^(a)~amlno-acids-#32-#129-_^of_F_igure 1 (SEQ ID NO: 2) ; 

(b) amino acids #299-#396 of Figure 2 (SEQ ID NO: 4) ; and 

(c) amino acids #311-#408 of Figure 3 (SEQ ID NO: 6). 

2. An osteogenic protein selected from the group consisting of: 

(a) a purified BME-2 protein produced by the steps of 

(I) culturlng\a cell transformed with 

(a) a cDNA comprising the nucleotide sequence 
from nucletotide #356 to #1543 as shown in Figure 

2 (SEQ ID NO: 3) ; and 

(b) sequences which hybridize to sequence 
under stringent conditions and encode a 
protein havind cartilage and/or bone induction 
activity \ 

(II) recovering andV^rlfying from said culture 
medium a protein pomjirlslng the 97 amino acid 
sequence from amino W2^<V#299 to amino acid #396 as 
shown in Figure 2 (SEQ ![D NO: 4) ; and 

(b) a purified BMP-4 protein Vroduced by the steps of 

(I) culturing a cell transformed with 

(a) a cDNA comprising^ the nucleotide sequence 
from nucleotide #403 to\#1626 as shown in Figure 

3 (SEQ ID NO: 5); and \ 

(b) sequences which hybridize to sequence (a) 
under stringent condltionsX and encode a 
protein having cartilage and/or bone Induction 
activity; \ 

(II) recovering from said culture Vedium a protein 
comprising the 97 amino acid sequence^from amino acid 
#311 to amino acid #408 as shown in Figure 3 (SEQ ID 
NO: 6). 



a 

03 

o 

01 

ru 
W 

Q 

w 
o 

a 



46 

3. A BMP-2 protein comprising amino acids #283-#396 of Figure 
2 (SEQ ID NO: 4) 

4. The protein of ^laim 3 wherein said protein is a disulfide 
~l-inked-dimer-whereiA-at-least_one__of the sxibunits of said dimer 



comprises amino acid\#283-#396 of Figure 2 (SEQ ID NO: 4) . 

5. A purified BMP-2 protein produced by the steps of 

(a) culturing a ceil transformed with a cDNA comprising 
the nucleotide sequence from nucleotide #356 to #1543 as 
shown in Figure 2 (SEQ ID NO: 3) ; and 

(b) recovering and puirifying from said culture medium a 
protein comprising the >97 amino acid sequence from amino 
acid #299 to amino acid \396 as shown in Figure 2 (SEQ ID 
NO: 4) . 



6. A BMP-4 protein comprising 
3 (SEQ ID NO: 6) . 



linoyiacids #293-#408 of Figure 



?• The protein of claim 6 wherein said protein is a disulfide 
linked dimer wherein at least one of\the sxibunits of said dimer 
comprises amino acid #293-#408 of FdWre 3 (SEQ ID NO: 6). 



8. A purified BMP-4 protein produced W the steps of 

(a) culturing a cell transformed With a cDNA comprising 
the nucleotide sequence from nuc led) tide #403 to #1626 as 
shown in Figure 3 (SEQ ID NO: 5); ahd 

(b) recovering form said culture\ medium a protein 
comprising the 97 amino acid sequence yrom amino acid #311 
to amino acid #408 as shown in Figure\3 (SEQ ID NO: 6) . 

9. A protein of claim 1 further characterised by the ability 
to induce the formation of cartilage and/or none. 



10. 



A pharmaceutical composition comprising* an effective 



amount of a BMP-2 protein in admixture with a pharmaceutically 
acceptable vehicle. , 

11. A pharmaceutical composition comprising an effective 
amount-of-a-BMpA4_protein in admixture with a pharmaceutically 
acceptable vehicle. 

12. A composition for bone and/or cartilage formation 
comprising an effective amount of a BMP-2 protein in a 
pharmaceutically acceptable vehicle. 

13. A compositionX for bone and/or cartilage formation 
comprising an effective amount of a BMP-4 protein in a 
pharmaceutically acceptable vehicle. 

14. A composition of cla^ 12 further comprising a matrix for 
supporting said composition^ and providing a surface for bone 
and/or cartilage growthl VA 

15. A composition of claim 13 further comprising a matrix for 
supporting said composition and providing a surface for bone 
and/or cartilage growth. \ 

16. The composition of claim 14\wherein said matrix comprises 
a material selected from Vhe group consisting of 
hydroxy apatite^ collagen, polylkctic acid and tricalcium 
phosphate. \ 

17. The composition of claim 15 whenein said matrix comprises 
a material selected from the \ group consisting of 
hydroxyapatite, collagen, polylactict acid and tricalcium 
phosphate . \ 

18. A method for inducing bone and/or cartilage formation in 
a patient in need of same comprising administering to said 



V 

patient an ef fective Wount of the composition of claim 11. 
19. A method for inducing bgne and/or cartilage formation in 
a patient in need of same comprising administering to said 
patient an effective amount of the composition of claim 11. 



20. A pharmaceutical composition for wound healing and tissue 
repair said composition comprising an effective amount of a 
BMP-2 protein in a pharmaceutically acceptable vehicle. 



21. A pharmaceutical composi€Sbn for wound healing and tissue 
repair said composition coiAprdJing an effective amdunt of a 
BMP-4 protein in a pharmaceutically acceptable vehicle. 



22. A method for treating wounas and/or tissue repair in a 
patient in need of S2uae comprising administering to said 
patient an effective amount of th A composition of claim 21. 

23. A method for treating wounds Mid/ or tissue repair in a 
patient in need of same comprisingr administering to said 
patient an effective amount of the coflmosition of claim 22.